About Natera, Inc. 
Natera, Inc.
Pharmaceuticals & Biotechnology
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).
Company Coordinates 
Company Details
201 Industrial Rd Ste 410 , SAN CARLOS CA : 94070-2396
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 113 Schemes (44.1%)
Foreign Institutions
Held by 291 Foreign Institutions (14.53%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Dr. Matthew Rabinowitz
Executive Chairman of the Board, Co-Founder
Mr. Steven Chapman
President, Chief Executive Officer, Director
Mr. Jonathan Sheena
Co-Founder, Chief Technology Officer, Director
Mr. Roelof Botha
Lead Independent Director
Mr. Roy Baynes
Independent Director
Dr. Monica Bertagnolli
Independent Director
Dr. Rowan Chapman
Independent Director
Mr. Todd Cozzens
Independent Director
Revenue and Profits:
Net Sales:
547 Million
(Quarterly Results - Jun 2025)
Net Profit:
-101 Million
Pharmaceuticals & Biotechnology
USD 22,974 Million (Mid Cap)
NA (Loss Making)
NA
0.00%
-0.74
-20.32%
18.44






